Kwon S J
Department of Surgery, Hanyang University Hospital, Seoul, Korea.
World J Surg. 1997 Oct;21(8):837-44. doi: 10.1007/s002689900314.
The relation between splenectomy and survival time after curative total gastrectomy for gastric cancer was reviewed retrospectively on 492 patients treated at nine hospitals between 1989 and 1993. Altogether 260 patients underwent splenectomy, and 232 patients did not. A univariate analysis revealed that the survival time of patients with splenectomy was significantly less than those without splenectomy (p = 0.0265). In a subgroup of our patients stratified to adjust for the stage of disease, there was no significant difference between the survival rates. Splenectomy remained insignificant according to the multivariate analysis using Cox's proportional-hazard regression. The splenectomy group was associated with more risk factors (e.g., T3/T4 tumors, positive nodes, stage greater than III, large tumor size) that are powerful predictors of death due to gastric cancer. In a separate multivariate analysis after eliminating those who had a T4 tumor invasion or a N2 nodal positivity from the analysis (or both), splenectomy again remained insignificant. In conclusion, we could not find any beneficial effect of splenectomy in gastric cancer patients in this retrospective multivariate analysis. We can presume that splenectomy cannot increase the survival rate so long as the splenectomy group has more risk factors than the nonsplenectomy group. Therefore randomized prospective clinical trials using more precise criteria to indicate the need for splenectomy are needed to assess whether splenectomy is beneficial.
回顾性分析了1989年至1993年间在9家医院接受治疗的492例胃癌患者,研究了根治性全胃切除术后脾切除术与生存时间的关系。共有260例患者接受了脾切除术,232例患者未接受。单因素分析显示,接受脾切除术的患者生存时间明显短于未接受脾切除术的患者(p = 0.0265)。在根据疾病分期分层的患者亚组中,生存率无显著差异。根据Cox比例风险回归进行的多因素分析显示,脾切除术仍然无显著意义。脾切除组与更多的危险因素相关(例如,T3/T4期肿瘤、阳性淋巴结、分期大于III期、肿瘤体积大),这些都是胃癌死亡的有力预测因素。在另一项多因素分析中,从分析中排除那些有T4肿瘤侵犯或N2淋巴结阳性(或两者皆有)的患者后,脾切除术再次无显著意义。总之,在这项回顾性多因素分析中,我们未发现脾切除术对胃癌患者有任何有益影响。我们可以推测,只要脾切除组的危险因素多于非脾切除组,脾切除术就不能提高生存率。因此,需要进行随机前瞻性临床试验,使用更精确的标准来表明是否需要脾切除术,以评估脾切除术是否有益。